cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B
Chronic hepatitis B virus infection (CHB) remains a global health concern, with currently available antiviral therapies demonstrating limited effectiveness in preventing hepatocellular carcinoma (HCC) development. Two primary challenges in CHB treatment include the persistence of the minichromosome,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124003272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227471794831360 |
|---|---|
| author | Patricia Gita Naully Marselina Irasonia Tan Agustiningsih Agustiningsih Caecilia Sukowati Ernawati Arifin Giri-Rachman |
| author_facet | Patricia Gita Naully Marselina Irasonia Tan Agustiningsih Agustiningsih Caecilia Sukowati Ernawati Arifin Giri-Rachman |
| author_sort | Patricia Gita Naully |
| collection | DOAJ |
| description | Chronic hepatitis B virus infection (CHB) remains a global health concern, with currently available antiviral therapies demonstrating limited effectiveness in preventing hepatocellular carcinoma (HCC) development. Two primary challenges in CHB treatment include the persistence of the minichromosome, covalently closed circular DNA (cccDNA) of the hepatitis B virus (HBV), and the failure of the host immune response to eliminate cccDNA. Recent findings indicate several host and HBV proteins involved in the epigenetic regulation of cccDNA, including HBV core protein (HBc) and HBV x protein (HBx). Both proteins might contribute to the stability of the cccDNA minichromosome and interact with viral and host proteins to support transcription. One potential avenue for CHB treatment involves the utilization of therapeutic vaccines. This paper explores HBV antigens suitable for epigenetic manipulation of cccDNA, elucidates their mechanisms of action, and evaluates their potential as key components of epigenetically-driven vaccines for CHB therapy. Molecular targeted agents with therapeutic vaccines offer a promising strategy for addressing CHB by targeting the virus and enhancing the host's immunological response. Despite challenges, the development of these vaccines provides new hope for CHB patients by emphasizing the need for HBV antigens that induce effective immune responses without causing T cell exhaustion. |
| format | Article |
| id | doaj-art-6bd2f4df41414c07bbde50ddf03e04b3 |
| institution | OA Journals |
| issn | 1665-2681 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj-art-6bd2f4df41414c07bbde50ddf03e04b32025-08-20T02:04:49ZengElsevierAnnals of Hepatology1665-26812025-01-0130110153310.1016/j.aohep.2024.101533cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis BPatricia Gita Naully0Marselina Irasonia Tan1Agustiningsih Agustiningsih2Caecilia Sukowati3Ernawati Arifin Giri-Rachman4School of Life Science and Technology, Institut Teknologi Bandung, Bandung 40132, Indonesia; Faculty of Health Sciences and Technology, Jenderal Achmad Yani University, Cimahi 40525, IndonesiaSchool of Life Science and Technology, Institut Teknologi Bandung, Bandung 40132, IndonesiaEijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, IndonesiaEijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia; Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Basovizza 34049, Trieste, ItalySchool of Life Science and Technology, Institut Teknologi Bandung, Bandung 40132, Indonesia; Corresponding author.Chronic hepatitis B virus infection (CHB) remains a global health concern, with currently available antiviral therapies demonstrating limited effectiveness in preventing hepatocellular carcinoma (HCC) development. Two primary challenges in CHB treatment include the persistence of the minichromosome, covalently closed circular DNA (cccDNA) of the hepatitis B virus (HBV), and the failure of the host immune response to eliminate cccDNA. Recent findings indicate several host and HBV proteins involved in the epigenetic regulation of cccDNA, including HBV core protein (HBc) and HBV x protein (HBx). Both proteins might contribute to the stability of the cccDNA minichromosome and interact with viral and host proteins to support transcription. One potential avenue for CHB treatment involves the utilization of therapeutic vaccines. This paper explores HBV antigens suitable for epigenetic manipulation of cccDNA, elucidates their mechanisms of action, and evaluates their potential as key components of epigenetically-driven vaccines for CHB therapy. Molecular targeted agents with therapeutic vaccines offer a promising strategy for addressing CHB by targeting the virus and enhancing the host's immunological response. Despite challenges, the development of these vaccines provides new hope for CHB patients by emphasizing the need for HBV antigens that induce effective immune responses without causing T cell exhaustion.http://www.sciencedirect.com/science/article/pii/S1665268124003272covalently closed circular DNAchronic hepatitis Bepigeneticimmune responsetherapeutic vaccine |
| spellingShingle | Patricia Gita Naully Marselina Irasonia Tan Agustiningsih Agustiningsih Caecilia Sukowati Ernawati Arifin Giri-Rachman cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B Annals of Hepatology covalently closed circular DNA chronic hepatitis B epigenetic immune response therapeutic vaccine |
| title | cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B |
| title_full | cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B |
| title_fullStr | cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B |
| title_full_unstemmed | cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B |
| title_short | cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B |
| title_sort | cccdna epigenetic regulator as target for therapeutical vaccine development against hepatitis b |
| topic | covalently closed circular DNA chronic hepatitis B epigenetic immune response therapeutic vaccine |
| url | http://www.sciencedirect.com/science/article/pii/S1665268124003272 |
| work_keys_str_mv | AT patriciagitanaully cccdnaepigeneticregulatorastargetfortherapeuticalvaccinedevelopmentagainsthepatitisb AT marselinairasoniatan cccdnaepigeneticregulatorastargetfortherapeuticalvaccinedevelopmentagainsthepatitisb AT agustiningsihagustiningsih cccdnaepigeneticregulatorastargetfortherapeuticalvaccinedevelopmentagainsthepatitisb AT caeciliasukowati cccdnaepigeneticregulatorastargetfortherapeuticalvaccinedevelopmentagainsthepatitisb AT ernawatiarifingirirachman cccdnaepigeneticregulatorastargetfortherapeuticalvaccinedevelopmentagainsthepatitisb |